Benefits
Lipid profile improvement
Multiple RCTs show spirulina reduces total cholesterol, LDL, and triglycerides while increasing HDL cholesterol. Meta-analyses confirm consistent lipid-lowering effects comparable to some pharmaceuticals at 4–8 g/day.
Antioxidant and anti-inflammatory
Phycocyanin is a potent antioxidant and selective COX-2 inhibitor. Supplementation significantly reduces CRP, IL-6, and MDA (lipid peroxidation marker) in clinical studies.
Immune enhancement
Spirulina polysaccharides activate macrophages, NK cells, and cytokine production. Studies show increased IgA secretion and improved immune response to influenza vaccination.
Blood sugar regulation
RCTs in type 2 diabetics show spirulina reduces fasting glucose, HbA1c, and postprandial glucose. Mechanism involves improved insulin sensitivity and reduced hepatic glucose output.
Mechanism of action
Phycocyanin antioxidant activity
C-phycocyanin directly scavenges hydroxyl radicals, peroxyl radicals, and peroxynitrite with higher potency than most plant polyphenols. It also inhibits NADPH oxidase, a key source of cellular ROS.
NF-κB and COX-2 inhibition
Phycocyanin inhibits NF-κB nuclear translocation, reducing transcription of inflammatory mediators including COX-2, TNF-α, and IL-6.
Lipid metabolism modulation
Spirulina upregulates LDL receptor expression in hepatocytes, increases bile acid synthesis from cholesterol, and may inhibit intestinal cholesterol absorption.
Clinical trials
Meta-analysis of 7 RCTs examining spirulina supplementation on lipid parameters.
522 participants across 7 RCTs.
Significant reductions in total cholesterol (−16 mg/dL), LDL (−10 mg/dL), and triglycerides (−44 mg/dL), with increase in HDL (+2 mg/dL). Effects dose-dependent.
RCT of spirulina (2 g/day) vs. placebo in 37 type 2 diabetic patients for 2 months.
37 T2DM patients. 2-month intervention.
Significant reductions in fasting glucose, HbA1c, triglycerides, and CRP. HDL increased significantly. Well-tolerated by all participants.